EGFR exon 20 insertions and how to manage patients in the UK

EGFR exon 20 insertion mutations represent 5% to 10% of EGFR mutations in patients with non-small cell lung cancer (NSCLC). Despite this form of lung cancer being hard to detect in standard genetic testing, mobocertinib and amivantamab have shown promising results in clinical trials.

In this week’s podcast, join Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, Alastair Greystoke, MBChB, MSc, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Anna Minchom, MD, MRCP, MBBCh, The Royal Marsden NHS Foundation Trust, London, UK, and Riyaz Shah, MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, as will discuss the identification of EGFR exon 20 insertions and how to manage patients in the UK, based on the recent decisions made by NICE on the use of amivantamab and mobocertinib.

The post EGFR exon 20 insertions and how to manage patients in the UK appeared first on VJOncology.